Premium
Fosfomycin Does Not Inhibit the Tumoricidal Efficacy of Cisplatinum
Author(s) -
Jordan Jennifer A.,
Schwade Nathan D.,
Truelson John M.
Publication year - 1999
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/00005537-199908000-00014
Subject(s) - fosfomycin , cisplatin , nephrotoxicity , in vivo , medicine , cancer research , pharmacology , in vitro , chemotherapy , toxicity , chemistry , biology , antibiotics , biochemistry , microbiology and biotechnology
Objectives: This study investigates the effect of fosfomycin on the tumoricidal efficacy of cisplatinum. Study Design: Prospective study utilizing the FaDu squamous cell carcinoma cell line and a nude mouse tumor xenograft model. Methods: Tumor cell growth was assessed in vitro in the presence of cisplatinum and/or fosfomycin utilizing the MTT assay. An optimal cisplatinum dose and dosing schedule was established in a nude mouse tumor xenograft model of squamous cell carcinoma. Using this model, fosfomycin was tested at three dosages and tumor growth monitored over 4 weeks. Results: Mice treated with cisplatinum and fosfomycin had smaller tumors than those treated with cisplatinum alone ( P < .01). Conclusions: This study is the first demonstration that fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum in vivo. This suggests that fosfomycin may be useful in preventing cisplatinum‐induced ototoxicity and nephrotoxicity in humans without altering the tumor response rate.